Term
| What other disease besides DM can metformin be used for |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| glimepiride/rosiglitazone |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| What is sulfonylureas main MOA |
|
Definition
binds to beta cells and increases secretion of insulin
(also has minimal effect on decreasing hepatic gluconeogenesis and increasing insulin sensitivity) |
|
|
Term
| Pts with liver disease are at risk for hypoglycemia while on which sulfonylureas |
|
Definition
|
|
Term
| Pts which renal insufficiencies (CrCl <50) are at risk for hypoglycemia while on which sulfonylureas |
|
Definition
|
|
Term
| When should sulfonylureas be taken |
|
Definition
|
|
Term
| What would be the ideal pt for a sulfonylurea |
|
Definition
| A1c <9% and NOT morbidly obese |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| What is the MOA of the meglitinides |
|
Definition
| Closes ATP-sensitive K+ channels on beta cells and increases insulin secretion |
|
|
Term
|
Definition
|
|
Term
|
Definition
decreases hepatic gluconeogenesis
(also increases insulin sensitivity, and decreases GI glucose absorption) |
|
|
Term
| which diabetic agent should be held for imaging studies with contrast dye |
|
Definition
|
|
Term
| at what SCr levels should metformin be stopped |
|
Definition
|
|
Term
| which diabetic medication has been shown to reduce macrovascular complications in obese pts |
|
Definition
|
|
Term
| which diabetic medication is good for pts with central obesity |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| what is the MOA of alpha-glucosidase inhibitors |
|
Definition
| prevents the breakdown of complex sugars to glucose |
|
|
Term
| if a pt on an alpha-glucosidase inhibitor has a hypoglycemic even, how would they treat it |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
activates PPAR receptor increasing insulin sensitivity
(also decreases hepatic gluconeogenesis) |
|
|
Term
| TZDs are contraindicated in which pts |
|
Definition
NYHA class III-IV HF
liver enzymes 2.5x ULN |
|
|
Term
|
Definition
|
|
Term
| what is the MOA of pramlintide |
|
Definition
| mimics exogenous amylin's effects and slows gastric emptying, suppression of glucagon secretion, and promotion of satiety |
|
|
Term
| how would you adjust a pts insulin dose when starting Symlin |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| how do incretin memetics work |
|
Definition
| Binds to and activates GLP1 receptors resulting in enhanced glucose-dependent insulin secretion, slowed gastric emptying, suppression of glucagon secretion, and promotion of satiety |
|
|
Term
| which diabetic drug class can cause acute pancreatitis |
|
Definition
|
|
Term
| which diabetic drug can cause thyroid cancer |
|
Definition
|
|
Term
| which two diabetic drug classes can cause weight LOSS |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| what is the MOA of Januvia |
|
Definition
| inhibits DPP-IV preventing the breakdown of endogenous incretins like GLP-1 |
|
|
Term
| which diabetic drug can cause Steve-Johnson's syndrome |
|
Definition
|
|
Term
Which of the following oral diabetic agents is most effective at lowering the A1c?
A. Glimepiride
B. Acarbose
C. Sitagliptin
D. They all lower the A1c equally well |
|
Definition
|
|
Term
| what is the only cloudy insulin |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Which insulin is available without a prescription |
|
Definition
|
|
Term
| what are the rapid acting insulins |
|
Definition
| lispro (Humalog), aspart (Novolog), glulisine (Apidra) |
|
|
Term
| what is the initial dosing for insulin |
|
Definition
|
|
Term
| what is the 2/3, 1/3 rule with insuline |
|
Definition
| give 2/3 of the daily dose of insulin in the AM and give 1/3 in the PM |
|
|
Term
| once opened, how long are insulin vials good for |
|
Definition
28 days
(execption detemir- 42 days) |
|
|
Term
| which insulins should not be mixed with others |
|
Definition
|
|
